Sort By
Publication Year
Deposit Date
Title
Type
Access
Publication Year
2018 (1)
2017 (1)
2016 (3)
2015 (2)
2014 (4)
2013 (4)
2012 (2)
2011 (1)
2010 (1)
2007 (3)
2004 (1)
2000 (1)
Version
M-Rank
M21 (3)
M22 (3)
M23 (13)

Vranić-Mandušić, Vesna

Link to this page

Authority KeyName Variants
orcid::0000-0002-2221-3707
  • Vranić-Mandušić, Vesna (1)
  • Vranić, Vesna (1)
  • Mandušić, Vesna (22)
Projects

Author's Bibliography

Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters

Todorović, Lidija; Stanojević, Boban; Mandušić, Vesna; Petrović, Nina; Zivaljevic, Vladan; Paunovic, Ivan; Diklić, Aleksandar; Saenko, Vladimir; Yamashita, Shunichi

(2018)

TY  - JOUR
AU  - Todorović, Lidija
AU  - Stanojević, Boban
AU  - Mandušić, Vesna
AU  - Petrović, Nina
AU  - Zivaljevic, Vladan
AU  - Paunovic, Ivan
AU  - Diklić, Aleksandar
AU  - Saenko, Vladimir
AU  - Yamashita, Shunichi
PY  - 2018
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1944
AB  - A growing body of evidence suggests a role of the von Hippel-Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up-or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069-0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109-19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = -0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified.
T2  - Medical Oncology
T1  - Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters
VL  - 35
IS  - 2
DO  - 10.1007/s12032-017-1066-3
ER  - 
@article{
author = "Todorović, Lidija and Stanojević, Boban and Mandušić, Vesna and Petrović, Nina and Zivaljevic, Vladan and Paunovic, Ivan and Diklić, Aleksandar and Saenko, Vladimir and Yamashita, Shunichi",
year = "2018",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1944",
abstract = "A growing body of evidence suggests a role of the von Hippel-Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up-or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069-0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109-19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = -0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified.",
journal = "Medical Oncology",
title = "Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters",
volume = "35",
number = "2",
doi = "10.1007/s12032-017-1066-3"
}
10
3
2
2

Genotyping Fanconi Anemia Patients from Serbia Reveals Three Novel Fancd2 Variants

Filipović Tričković, Jelena G.; Mandušić, Vesna; Joksić, Ivana; Vujic, Dragana; Valenta-Šobot, Ana; Joksić, Gordana

(2017)

TY  - JOUR
AU  - Filipović Tričković, Jelena G.
AU  - Mandušić, Vesna
AU  - Joksić, Ivana
AU  - Vujic, Dragana
AU  - Valenta-Šobot, Ana
AU  - Joksić, Gordana
PY  - 2017
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1882
AB  - Fanconi anemia is rare inherited disease characterized by wide spectrum of congenital anomalies, progressive pancytopenia, and predisposition to hematological malignancies and solid tumors. Molecular genetic analysis of mutations in FANC genes is of a great importance for diagnosis confirmation, prenatal and carrier testing, as well as for prediction of chemotherapy outcome and disease complications. In this study we performed screening of frequently affected regions of FANCD2 gene for sequence variants in six unrelated FA-D2 patients in Serbia. This is the first molecular analysis of FANCD2 gene in Serbian FA-D2 patients. A total of 10 sequence variants were detected, one in homozygous, and nine in heterozygous state. Two variants were found within exons, and eight within introns, in deep intronic regions. In-silico analysis showed that among all detected variants one exon variant and three intron variants might have impact on splicing mechanism. Heterozygous variants found in intron 3, c. 206-246delG; exon 26, c. 2396 C GT A and intron 28, c. 2715+573 C GT T were not previously reported. In-silico analysis revealed that among them, two (intron 3, c. 206-246 delG and exon 26, c. 2396 C GT A) could be novel disease-causing mutations. Many variants were found in more than one patient, including those unreported, indicating their possible ethnic association. Great number of variants in some patients suggests their non-random emergence in Fanconi anemia pathway.
T2  - Genetika (Beograd)
T1  - Genotyping Fanconi Anemia Patients from Serbia Reveals Three Novel Fancd2 Variants
VL  - 49
IS  - 2
SP  - 559
EP  - 572
DO  - 10.2298/GENSR1702559T
ER  - 
@article{
author = "Filipović Tričković, Jelena G. and Mandušić, Vesna and Joksić, Ivana and Vujic, Dragana and Valenta-Šobot, Ana and Joksić, Gordana",
year = "2017",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1882",
abstract = "Fanconi anemia is rare inherited disease characterized by wide spectrum of congenital anomalies, progressive pancytopenia, and predisposition to hematological malignancies and solid tumors. Molecular genetic analysis of mutations in FANC genes is of a great importance for diagnosis confirmation, prenatal and carrier testing, as well as for prediction of chemotherapy outcome and disease complications. In this study we performed screening of frequently affected regions of FANCD2 gene for sequence variants in six unrelated FA-D2 patients in Serbia. This is the first molecular analysis of FANCD2 gene in Serbian FA-D2 patients. A total of 10 sequence variants were detected, one in homozygous, and nine in heterozygous state. Two variants were found within exons, and eight within introns, in deep intronic regions. In-silico analysis showed that among all detected variants one exon variant and three intron variants might have impact on splicing mechanism. Heterozygous variants found in intron 3, c. 206-246delG; exon 26, c. 2396 C GT A and intron 28, c. 2715+573 C GT T were not previously reported. In-silico analysis revealed that among them, two (intron 3, c. 206-246 delG and exon 26, c. 2396 C GT A) could be novel disease-causing mutations. Many variants were found in more than one patient, including those unreported, indicating their possible ethnic association. Great number of variants in some patients suggests their non-random emergence in Fanconi anemia pathway.",
journal = "Genetika (Beograd)",
title = "Genotyping Fanconi Anemia Patients from Serbia Reveals Three Novel Fancd2 Variants",
volume = "49",
number = "2",
pages = "559-572",
doi = "10.2298/GENSR1702559T"
}

The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia

Jovanović-Ćupić, Snežana P.; Glišić, Sanja; Stanojevic, Maja; Nozic, Darko; Petrović, Nina; Mandušić, Vesna; Krajnović, Milena M.

(2016)

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, Maja
AU  - Nozic, Darko
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1032
AB  - The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.
T2  - Archives of Virology
T1  - The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia
VL  - 161
IS  - 5
SP  - 1189
EP  - 1198
DO  - 10.1007/s00705-016-2777-z
ER  - 
@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, Maja and Nozic, Darko and Petrović, Nina and Mandušić, Vesna and Krajnović, Milena M.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1032",
abstract = "The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.",
journal = "Archives of Virology",
title = "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia",
volume = "161",
number = "5",
pages = "1189-1198",
doi = "10.1007/s00705-016-2777-z"
}
1
1

miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis

Petrović, Nina; Kolaković, Ana; Stanković, Aleksandra; Lukic, Silvana; Sami, Ahmad; Živković, Maja; Mandušić, Vesna

(2016)

TY  - JOUR
AU  - Petrović, Nina
AU  - Kolaković, Ana
AU  - Stanković, Aleksandra
AU  - Lukic, Silvana
AU  - Sami, Ahmad
AU  - Živković, Maja
AU  - Mandušić, Vesna
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1023
AB  - BACKGROUND: Breast carcinoma is heterogeneous disease. Understanding the process of invasion and metastasis and the selection of the therapy for patients with breast carcinomas still remains difficult. MicroRNAs are powerful gene expression regulators. Because of inconsistent findings, we have analyzed potential difference in miR-155 levels in three breast cancer groups. OBJECTIVES: Our goals were to examine miR-155 expression levels in normal tissue, non-invasive and invasive breast carcinomas, and their association with standard clinical and pathological parameters and oncomiR-21, and to investigate the ability of miR-155 to separate invasive breast carcinomas with non-invasive component from pure invasive. METHODS: In the group of 40 breast tissue samples, relative expression levels of miR-155 were examined with stem-loop quantitative real-time PCR using TaqMan technology. RESULTS: The significant difference among four examined groups of the breast tissue was detected (p = 0.001). In the group of pure invasive tumors, patients with positive nodal status had significantly higher miR-155 levels (p = 0.046). CONCLUSION: Our results suggest that miR-155 might be involved in breast cancer pathogenesis and in tumor spreading to the lymph nodes, and that it might be used as biomarker for additional stratification of patients with invasive breast carcinomas with non-invasive component.
T2  - Cancer Biomarkers
T1  - miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis
VL  - 16
IS  - 3
SP  - 385
EP  - 394
DO  - 10.3233/CBM-160577
ER  - 
@article{
author = "Petrović, Nina and Kolaković, Ana and Stanković, Aleksandra and Lukic, Silvana and Sami, Ahmad and Živković, Maja and Mandušić, Vesna",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1023",
abstract = "BACKGROUND: Breast carcinoma is heterogeneous disease. Understanding the process of invasion and metastasis and the selection of the therapy for patients with breast carcinomas still remains difficult. MicroRNAs are powerful gene expression regulators. Because of inconsistent findings, we have analyzed potential difference in miR-155 levels in three breast cancer groups. OBJECTIVES: Our goals were to examine miR-155 expression levels in normal tissue, non-invasive and invasive breast carcinomas, and their association with standard clinical and pathological parameters and oncomiR-21, and to investigate the ability of miR-155 to separate invasive breast carcinomas with non-invasive component from pure invasive. METHODS: In the group of 40 breast tissue samples, relative expression levels of miR-155 were examined with stem-loop quantitative real-time PCR using TaqMan technology. RESULTS: The significant difference among four examined groups of the breast tissue was detected (p = 0.001). In the group of pure invasive tumors, patients with positive nodal status had significantly higher miR-155 levels (p = 0.046). CONCLUSION: Our results suggest that miR-155 might be involved in breast cancer pathogenesis and in tumor spreading to the lymph nodes, and that it might be used as biomarker for additional stratification of patients with invasive breast carcinomas with non-invasive component.",
journal = "Cancer Biomarkers",
title = "miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis",
volume = "16",
number = "3",
pages = "385-394",
doi = "10.3233/CBM-160577"
}
1
15
14
13

Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue

Ivanovic, Vesna; Dedović-Tanić, Nasta; Milovanović, Zorka M.; Lukic, Silvana; Nikolic, Srdjan; Baltic, Vladimir; Stojiljkovic, Bratislav; Demajo, Miroslav; Mandušić, Vesna; Dimitrijević, Bogomir B.

(2016)

TY  - JOUR
AU  - Ivanovic, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukic, Silvana
AU  - Nikolic, Srdjan
AU  - Baltic, Vladimir
AU  - Stojiljkovic, Bratislav
AU  - Demajo, Miroslav
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1327
AB  - We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.
T2  - Personalized Medicine
T1  - Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue
VL  - 13
IS  - 6
SP  - 523
EP  - 530
DO  - 10.2217/pme-2016-0032
ER  - 
@article{
author = "Ivanovic, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukic, Silvana and Nikolic, Srdjan and Baltic, Vladimir and Stojiljkovic, Bratislav and Demajo, Miroslav and Mandušić, Vesna and Dimitrijević, Bogomir B.",
year = "2016",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/1327",
abstract = "We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.",
journal = "Personalized Medicine",
title = "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue",
volume = "13",
number = "6",
pages = "523-530",
doi = "10.2217/pme-2016-0032"
}
1
1
1
1

Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease

Bajić, Vladan P.; Mandušić, Vesna; Stefanova, Elka; Božović, Ana M.; Davidović, Radoslav S.; Živković, Lada; Cabarkapa, Andrea; Spremo-Potparević, Biljana

(2015)

TY  - JOUR
AU  - Bajić, Vladan P.
AU  - Mandušić, Vesna
AU  - Stefanova, Elka
AU  - Božović, Ana M.
AU  - Davidović, Radoslav S.
AU  - Živković, Lada
AU  - Cabarkapa, Andrea
AU  - Spremo-Potparević, Biljana
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/314
AB  - X-chromosome instability has been a long established feature in Alzheimers disease ( AD). Premature centromere division and aneuploidy of the X-chromosome has been found in peripheral blood lymphocytes and neuronal tissue in female AD patients. Interestingly, only one chromosome of the X pair has been affected. These results raised a question, Is the X-chromosome inactivation pattern altered in peripheral blood lymphocytes ofwomen affected by AD? To address this question, we analyzed the methylation status of androgen receptor promoter which may show us any deviation from the 50 : 50% X inactivation status in peripheral blood lymphocytes ofwomen with AD. Our results showed skewed inactivation patterns ( GT 90%). These findings suggest that an epigenetic alteration on the inactivation centers of the X-chromosome (or skewing) relates not only to aging, by might be a novel property that could account for the higher incidence of AD in women.
T2  - Journal of Alzheimers Disease
T1  - Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease
VL  - 43
IS  - 4
SP  - 1251
EP  - 1259
DO  - 10.3233/JAD-141674
ER  - 
@article{
author = "Bajić, Vladan P. and Mandušić, Vesna and Stefanova, Elka and Božović, Ana M. and Davidović, Radoslav S. and Živković, Lada and Cabarkapa, Andrea and Spremo-Potparević, Biljana",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/314",
abstract = "X-chromosome instability has been a long established feature in Alzheimers disease ( AD). Premature centromere division and aneuploidy of the X-chromosome has been found in peripheral blood lymphocytes and neuronal tissue in female AD patients. Interestingly, only one chromosome of the X pair has been affected. These results raised a question, Is the X-chromosome inactivation pattern altered in peripheral blood lymphocytes ofwomen affected by AD? To address this question, we analyzed the methylation status of androgen receptor promoter which may show us any deviation from the 50 : 50% X inactivation status in peripheral blood lymphocytes ofwomen with AD. Our results showed skewed inactivation patterns ( GT 90%). These findings suggest that an epigenetic alteration on the inactivation centers of the X-chromosome (or skewing) relates not only to aging, by might be a novel property that could account for the higher incidence of AD in women.",
journal = "Journal of Alzheimers Disease",
title = "Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease",
volume = "43",
number = "4",
pages = "1251-1259",
doi = "10.3233/JAD-141674"
}
1
8
11
10

Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component

Petrović, Nina; Jovanović-Ćupić, Snežana P.; Brajuskovic, Goran; Lukic, Silvana; Roganović, Jelena; Krajnović, Milena M.; Mandušić, Vesna

(2015)

TY  - JOUR
AU  - Petrović, Nina
AU  - Jovanović-Ćupić, Snežana P.
AU  - Brajuskovic, Goran
AU  - Lukic, Silvana
AU  - Roganović, Jelena
AU  - Krajnović, Milena M.
AU  - Mandušić, Vesna
PY  - 2015
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/862
AB  - Invasive ductal carcinomas with a non-invasive component (IDC-DCIS) are classified as a group of invasive breast carcinomas, together with pure invasive ductal carcinomas of the breast (IDC). MicroRNA-21 (miR-21) has been characterized as a factor of breast cancer invasiveness, however the difference in miR-21 expression levels between IDC-DCIS and pure IDC tumors and the correlations with standard diagnostic and prognostic parameters inside the IDC-DCIS group are unknown. Our aim was to determine if miR-21 had the ability to distinguish these two invasive breast cancer groups. Levels of miR-21 expression were measured by a stem-loop quantitative Real-Time PCR (RT-qPCR) method. Expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and proliferative index Ki-67 were evaluated by immunohistochemistry. IDC-DCIS tumors had significantly lower levels of miR-21 expression in grade 2 (P=0.003, Mann-Whitney U test), ER positive (P=0.025, Mann-Whitney U test) and PR positive tumors (P=0.024, Mann-Whitney U test) than pure IDCs. miR-21 levels showed a different pattern of expression in IDC-DCIS compared to IDC tumors, which is based on the difference in miR-21 expression between Her-2 negative and Her-2 positive IDC-DCIS tumors (P=0.030, Mann-Whitney U test) and high negative correlation of miR-21 levels with PR levels (rho=-0.886, P=0.006, Spearman correlation). According to our results, IDC-DCIS breast carcinomas act in a different manner in pure IDC tumors with regard to the relations between miR-21 expression levels and the standard diagnostic and prognostic parameters, such as Her-2 status, ER and PR status and protein levels.
T2  - Archives of biological sciences
T1  - Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component
VL  - 67
IS  - 4
SP  - 1285
EP  - 1295
DO  - 10.2298/ABS150327105P
ER  - 
@article{
author = "Petrović, Nina and Jovanović-Ćupić, Snežana P. and Brajuskovic, Goran and Lukic, Silvana and Roganović, Jelena and Krajnović, Milena M. and Mandušić, Vesna",
year = "2015",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/862",
abstract = "Invasive ductal carcinomas with a non-invasive component (IDC-DCIS) are classified as a group of invasive breast carcinomas, together with pure invasive ductal carcinomas of the breast (IDC). MicroRNA-21 (miR-21) has been characterized as a factor of breast cancer invasiveness, however the difference in miR-21 expression levels between IDC-DCIS and pure IDC tumors and the correlations with standard diagnostic and prognostic parameters inside the IDC-DCIS group are unknown. Our aim was to determine if miR-21 had the ability to distinguish these two invasive breast cancer groups. Levels of miR-21 expression were measured by a stem-loop quantitative Real-Time PCR (RT-qPCR) method. Expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and proliferative index Ki-67 were evaluated by immunohistochemistry. IDC-DCIS tumors had significantly lower levels of miR-21 expression in grade 2 (P=0.003, Mann-Whitney U test), ER positive (P=0.025, Mann-Whitney U test) and PR positive tumors (P=0.024, Mann-Whitney U test) than pure IDCs. miR-21 levels showed a different pattern of expression in IDC-DCIS compared to IDC tumors, which is based on the difference in miR-21 expression between Her-2 negative and Her-2 positive IDC-DCIS tumors (P=0.030, Mann-Whitney U test) and high negative correlation of miR-21 levels with PR levels (rho=-0.886, P=0.006, Spearman correlation). According to our results, IDC-DCIS breast carcinomas act in a different manner in pure IDC tumors with regard to the relations between miR-21 expression levels and the standard diagnostic and prognostic parameters, such as Her-2 status, ER and PR status and protein levels.",
journal = "Archives of biological sciences",
title = "Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component",
volume = "67",
number = "4",
pages = "1285-1295",
doi = "10.2298/ABS150327105P"
}
2
2
2

The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion

Petrović, Nina; Mandušić, Vesna; Stanojević, Boban; Lukic, Silvana; Todorović, Lidija; Roganović, Jelena; Dimitrijević, Bogomir B.

(2014)

TY  - JOUR
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Stanojević, Boban
AU  - Lukic, Silvana
AU  - Todorović, Lidija
AU  - Roganović, Jelena
AU  - Dimitrijević, Bogomir B.
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6041
AB  - MicroRNA-21 (miR-21) overexpression is characteristic for various types of tumors, but it is still unknown whether its expression levels differ between invasive and non-invasive breast carcinomas. The main goal of the study was to determine the difference in miR-21 expression among normal tissue, non-invasive, invasive with non-invasive component, and pure invasive breast cancer samples, to explain its potential role and significance in breast cancer invasiveness. The second goal was to propose miR-21 as molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis. In order to reveal the role of miR-21 in breast cancer invasiveness, we measured miR-21 expression levels in 44 breast cancer and four normal samples by stem-loop real-time RT-PCR using TaqMan technology. Relative expression levels of miR-21 were significantly higher in invasive than in other groups (P = 0.002) and significantly higher in invasive compared with invasive with non-invasive component group in histological (P = 0.043) and nuclear grade 2 (P = 0.036), estrogen-receptor-positive (ER+) (P = 0.006), progesterone-receptor-positive (PR+) (P = 0.008), ER+ PR+ (P = 0.007), and proliferation index (Ki-67) LT = 20 % (P = 0.036) tumors. Our findings suggest that miR-21 could be independent molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis.
T2  - Medical Oncology
T1  - The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion
VL  - 31
IS  - 3
DO  - 10.1007/s12032-014-0867-x
ER  - 
@article{
author = "Petrović, Nina and Mandušić, Vesna and Stanojević, Boban and Lukic, Silvana and Todorović, Lidija and Roganović, Jelena and Dimitrijević, Bogomir B.",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/6041",
abstract = "MicroRNA-21 (miR-21) overexpression is characteristic for various types of tumors, but it is still unknown whether its expression levels differ between invasive and non-invasive breast carcinomas. The main goal of the study was to determine the difference in miR-21 expression among normal tissue, non-invasive, invasive with non-invasive component, and pure invasive breast cancer samples, to explain its potential role and significance in breast cancer invasiveness. The second goal was to propose miR-21 as molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis. In order to reveal the role of miR-21 in breast cancer invasiveness, we measured miR-21 expression levels in 44 breast cancer and four normal samples by stem-loop real-time RT-PCR using TaqMan technology. Relative expression levels of miR-21 were significantly higher in invasive than in other groups (P = 0.002) and significantly higher in invasive compared with invasive with non-invasive component group in histological (P = 0.043) and nuclear grade 2 (P = 0.036), estrogen-receptor-positive (ER+) (P = 0.006), progesterone-receptor-positive (PR+) (P = 0.008), ER+ PR+ (P = 0.007), and proliferation index (Ki-67) LT = 20 % (P = 0.036) tumors. Our findings suggest that miR-21 could be independent molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis.",
journal = "Medical Oncology",
title = "The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion",
volume = "31",
number = "3",
doi = "10.1007/s12032-014-0867-x"
}
1
36
26
38

Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia

Petrović, Nina; Mandušić, Vesna; Dimitrijević, Bogomir B.; Roganović, Jelena; Lukic, Silvana; Todorović, Lidija; Stanojević, Boban

(2014)

TY  - JOUR
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
AU  - Roganović, Jelena
AU  - Lukic, Silvana
AU  - Todorović, Lidija
AU  - Stanojević, Boban
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/6070
AB  - MicroRNAs play essential role in breast carcinoma progression and invasion. Our principal goals were to assess clinicopathological and prognostic correlations of microRNA-21 (miR-21) expression levels in a group of 39 Serbian breast cancer patients with invasive lobular (ILC), ductal (IDC), or mixed (ILC-IDC) breast carcinomas and in order to discover the role of miR-21 in potential novel form of stratification of the patients with different estrogen receptor (ER) and progesterone receptor (PR) status. MiR-21 expression levels were measured by stem-loop real-time RT-PCR using TaqMan technology. ER, PR, human epidermal growth factor 2 receptor (Her-2), and proliferative index (Ki-67) were evaluated by immunohistochemistry. MiR-21 levels do not vary among ILC, IDC, and ILC-IDC subgroups. MiR-21 expression levels varied significantly in the age, tumor size, Ki-67, and different grade (p = 0.030, p = 0.036, p = 0.027 and p = 0.032, respectively) subgroups. ER? and PR? showed higher miR-21 levels than their negative receptor status paired groups ER-and PR-with p = 0.012 and p = 0.018, respectively. MiR-21 positively correlated with ER and PR status (p = 0.018, rho = 0.379 and p = 0.034, rho = 0.345, respectively). Our findings suggest that miR-21 emulates transitional form of expression and that the levels of expression might be useful for stratification of the patients with different receptor status with the purpose to seek for new therapy approaches especially for the patients with the lack of response to conventional endocrine therapy.
T2  - Medical Oncology
T1  - Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia
VL  - 31
IS  - 6
DO  - 10.1007/s12032-014-0977-5
ER  - 
@article{
author = "Petrović, Nina and Mandušić, Vesna and Dimitrijević, Bogomir B. and Roganović, Jelena and Lukic, Silvana and Todorović, Lidija and Stanojević, Boban",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/6070",
abstract = "MicroRNAs play essential role in breast carcinoma progression and invasion. Our principal goals were to assess clinicopathological and prognostic correlations of microRNA-21 (miR-21) expression levels in a group of 39 Serbian breast cancer patients with invasive lobular (ILC), ductal (IDC), or mixed (ILC-IDC) breast carcinomas and in order to discover the role of miR-21 in potential novel form of stratification of the patients with different estrogen receptor (ER) and progesterone receptor (PR) status. MiR-21 expression levels were measured by stem-loop real-time RT-PCR using TaqMan technology. ER, PR, human epidermal growth factor 2 receptor (Her-2), and proliferative index (Ki-67) were evaluated by immunohistochemistry. MiR-21 levels do not vary among ILC, IDC, and ILC-IDC subgroups. MiR-21 expression levels varied significantly in the age, tumor size, Ki-67, and different grade (p = 0.030, p = 0.036, p = 0.027 and p = 0.032, respectively) subgroups. ER? and PR? showed higher miR-21 levels than their negative receptor status paired groups ER-and PR-with p = 0.012 and p = 0.018, respectively. MiR-21 positively correlated with ER and PR status (p = 0.018, rho = 0.379 and p = 0.034, rho = 0.345, respectively). Our findings suggest that miR-21 emulates transitional form of expression and that the levels of expression might be useful for stratification of the patients with different receptor status with the purpose to seek for new therapy approaches especially for the patients with the lack of response to conventional endocrine therapy.",
journal = "Medical Oncology",
title = "Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia",
volume = "31",
number = "6",
doi = "10.1007/s12032-014-0977-5"
}
8
11
9

Methylation-specific PCR: four steps in primer design

Davidović, Radoslav S.; Božović, Ana M.; Mandušić, Vesna; Krajnović, Milena M.

(2014)

@article{
author = "Davidović, Radoslav S. and Božović, Ana M. and Mandušić, Vesna and Krajnović, Milena M.",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/74",
abstract = "Methylation-specific PCR (MSP) is still the method of choice for a single gene methylation study. The proper design of the primer pairs is a prerequisite for obtaining reliable PCR results. Despite numerous protocols describing the rules for MSP primer design, none of them provide a comprehensive approach to the problem. Our aim was to depict a workflow for the primer design that is concise and easy to follow. In order to achieve this goal, adequate tools for promoter sequence retrieval, MSP primer design and subsequent in silico analysis are presented and discussed. Furthermore, a few instructive examples regarding a good versus a poor primer design are provided. Finally, primer design is demonstrated according to the proposed workflow. This article aims to provide researchers, interested in a single gene methylation studies, with useful information regarding successful primer design.",
journal = "Central European Journal of Biology",
title = "Methylation-specific PCR: four steps in primer design",
volume = "9",
number = "12",
pages = "1127-1139",
doi = "10.2478/s11535-014-0324-z"
}
6
5
4

Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up

Markicevic, Milan; Dzodic, Radan; Buta, Marko; Kanjer, Ksenija; Mandušić, Vesna; Neskovic-Konstantinovic, Zora; Nikolic-Vukosavljevic, Dragica

(2014)

TY  - JOUR
AU  - Markicevic, Milan
AU  - Dzodic, Radan
AU  - Buta, Marko
AU  - Kanjer, Ksenija
AU  - Mandušić, Vesna
AU  - Neskovic-Konstantinovic, Zora
AU  - Nikolic-Vukosavljevic, Dragica
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/203
AB  - Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
T2  - International Journal of Medical Sciences
T1  - Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up
VL  - 11
IS  - 7
SP  - 663
EP  - 673
DO  - 10.7150/ijms.8194
ER  - 
@article{
author = "Markicevic, Milan and Dzodic, Radan and Buta, Marko and Kanjer, Ksenija and Mandušić, Vesna and Neskovic-Konstantinovic, Zora and Nikolic-Vukosavljevic, Dragica",
year = "2014",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/203",
abstract = "Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.",
journal = "International Journal of Medical Sciences",
title = "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up",
volume = "11",
number = "7",
pages = "663-673",
doi = "10.7150/ijms.8194"
}
9
11
10

p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma

Davidović, Radoslav S.; Sopta, Jelena; Mandušić, Vesna; Krajnović, Milena M.; Stanojevic, Maja; Tulic, Goran; Dimitrijević, Bogomir B.

(2013)

TY  - JOUR
AU  - Davidović, Radoslav S.
AU  - Sopta, Jelena
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
AU  - Stanojevic, Maja
AU  - Tulic, Goran
AU  - Dimitrijević, Bogomir B.
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5646
AB  - Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.
T2  - Medical Oncology
T1  - p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma
VL  - 30
IS  - 3
DO  - 10.1007/s12032-013-0682-9
ER  - 
@article{
author = "Davidović, Radoslav S. and Sopta, Jelena and Mandušić, Vesna and Krajnović, Milena M. and Stanojevic, Maja and Tulic, Goran and Dimitrijević, Bogomir B.",
year = "2013",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5646",
abstract = "Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.",
journal = "Medical Oncology",
title = "p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma",
volume = "30",
number = "3",
doi = "10.1007/s12032-013-0682-9"
}
6
4
4

Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer

Božović, Ana M.; Markicevic, Milan; Dimitrijević, Bogomir B.; Jovanović-Ćupić, Snežana P.; Krajnović, Milena M.; Lukic, Silvana; Mandušić, Vesna

(2013)

TY  - JOUR
AU  - Božović, Ana M.
AU  - Markicevic, Milan
AU  - Dimitrijević, Bogomir B.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Krajnović, Milena M.
AU  - Lukic, Silvana
AU  - Mandušić, Vesna
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5647
AB  - The aim of the study was to assess how hypermethylation of the ON promoter of the estrogen receptor beta (ER beta) gene affects its expression (at the mRNA and protein level) and to correlate these with some clinical and histopathological parameters. A total of 131 samples of frozen breast cancer tissue was analyzed. A custom-designed, two-step PCR method was used to measure the methylation index of the ER beta gene ON promoter region. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to quantify mRNA of the ER beta 1 isoform, while ER beta 1 protein was determined using the Western blot method. There was a significant difference in the methylation index of the ER beta gene ON promoter between the groups of patients with negative and positive axillary lymph node status (P = 0.03). In addition, the methylation index of the ON promoter was positively correlated with estrogen receptor alfa (ER alpha) protein levels (q = 0.31, P = 0.02). There was a significant difference in the methylation index of the ON promoter between the progesterone receptor (PR)-negative and PR-positive groups of patients (P = 0.01). ER beta 1 protein levels were negatively correlated with ER alpha protein (q = -0.27, P LT 0.01). The methylation index of the ON promoter could be a more reliable additional parameter for prediction and/or prognosis in breast cancer than ER beta 1-mRNA and/or protein levels.
T2  - Medical Oncology
T1  - Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer
VL  - 30
IS  - 3
DO  - 10.1007/s12032-013-0642-4
ER  - 
@article{
author = "Božović, Ana M. and Markicevic, Milan and Dimitrijević, Bogomir B. and Jovanović-Ćupić, Snežana P. and Krajnović, Milena M. and Lukic, Silvana and Mandušić, Vesna",
year = "2013",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5647",
abstract = "The aim of the study was to assess how hypermethylation of the ON promoter of the estrogen receptor beta (ER beta) gene affects its expression (at the mRNA and protein level) and to correlate these with some clinical and histopathological parameters. A total of 131 samples of frozen breast cancer tissue was analyzed. A custom-designed, two-step PCR method was used to measure the methylation index of the ER beta gene ON promoter region. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to quantify mRNA of the ER beta 1 isoform, while ER beta 1 protein was determined using the Western blot method. There was a significant difference in the methylation index of the ER beta gene ON promoter between the groups of patients with negative and positive axillary lymph node status (P = 0.03). In addition, the methylation index of the ON promoter was positively correlated with estrogen receptor alfa (ER alpha) protein levels (q = 0.31, P = 0.02). There was a significant difference in the methylation index of the ON promoter between the progesterone receptor (PR)-negative and PR-positive groups of patients (P = 0.01). ER beta 1 protein levels were negatively correlated with ER alpha protein (q = -0.27, P LT 0.01). The methylation index of the ON promoter could be a more reliable additional parameter for prediction and/or prognosis in breast cancer than ER beta 1-mRNA and/or protein levels.",
journal = "Medical Oncology",
title = "Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer",
volume = "30",
number = "3",
doi = "10.1007/s12032-013-0642-4"
}
3
4
4

Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period

Balint, Bela; Vucetic, Dusan; Todorovic-Balint, Milena; Borovcanin, Nemanja; Jovanović-Ćupić, Snežana P.; Mandušić, Vesna

(2013)

@article{
author = "Balint, Bela and Vucetic, Dusan and Todorovic-Balint, Milena and Borovcanin, Nemanja and Jovanović-Ćupić, Snežana P. and Mandušić, Vesna",
year = "2013",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5682",
journal = "Transfusion and Apheresis Science",
title = "Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period",
volume = "49",
number = "1",
pages = "103-104",
doi = "10.1016/j.transci.2012.09.008"
}
3
4
4

Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up

Markicevic, Milan; Kanjer, Ksenija; Mandušić, Vesna; Buta, Marko; Neskovic-Konstantinovic, Zora; Nikolic-Vukosavljevic, Dragica

(2013)

TY  - JOUR
AU  - Markicevic, Milan
AU  - Kanjer, Ksenija
AU  - Mandušić, Vesna
AU  - Buta, Marko
AU  - Neskovic-Konstantinovic, Zora
AU  - Nikolic-Vukosavljevic, Dragica
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5683
AB  - Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
T2  - Biomarkers in Medicine
T1  - Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up
VL  - 7
IS  - 5
SP  - 747
EP  - 758
DO  - 10.2217/bmm.13.62
ER  - 
@article{
author = "Markicevic, Milan and Kanjer, Ksenija and Mandušić, Vesna and Buta, Marko and Neskovic-Konstantinovic, Zora and Nikolic-Vukosavljevic, Dragica",
year = "2013",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5683",
abstract = "Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.",
journal = "Biomarkers in Medicine",
title = "Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up",
volume = "7",
number = "5",
pages = "747-758",
doi = "10.2217/bmm.13.62"
}
6
6
5

Effect of Chronic Forced Running on Gene Expression of Catecholamine Biosynthetic Enzymes in Stellate Ganglia of Rats

Gavrilović, Ljubica; Mandušić, Vesna; Stojiljković, Vesna; Kasapović, Jelena; Stojiljkovic, S.; Pajović, Snežana B.; Dronjak, Slađana

(2012)

TY  - JOUR
AU  - Gavrilović, Ljubica
AU  - Mandušić, Vesna
AU  - Stojiljković, Vesna
AU  - Kasapović, Jelena
AU  - Stojiljkovic, S.
AU  - Pajović, Snežana B.
AU  - Dronjak, Slađana
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5112
AB  - The sympathoneural system has a profound influence on the heart function. Sympathetic neurons are the major contributors to the huge rise of circulating noradrenaline (NA) level in response to stressful stimuli. Treadmill training in rats is forced exercise which has the propensity to induce both psychological and physical stress. The aim of this study is to examine how chronic forced running (CFR) affects the expression of catecholamine biosynthetic enzymes (tyrosine hydroxylase (TH), dopamine-beta-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT)) and cAMP response element-binding (CREB) in stellate ganglia, as well as the concentrations of catecholamines, adrenocorticotropic hormone (ACTH) and corticosterone (CORT) in the plasma of rats. Also, we investigated how the additional acute immobilization stress changes the mentioned parameters. The rat training program consisted of 12 weeks running on a treadmill (20 m/min, 20 min/day). We found that CFR increases TH and DBH mRNA and protein levels in stellate ganglia, which is followed by increased NA concentration in the plasma. CFR reduces the level of PNMT m RNA, while the level of PNMT protein remains unchanged in stellate ganglia. The increased expression of TH and DBH genes positively correlates with the expression of CREB in stellate ganglia and with plasma ACTH level, while reduced level of PNMT mRNA in stellate ganglia correlates with reduced plasma CORT level. The additional acute immobilization stress increased gene expression of catecholamine biosynthetic enzymes in stellate ganglia, as well as catecholamines, ACTH and CORT levels in the plasma. The results presented here suggest that the continuous increase of the noradrenaline biosynthetic enzyme expression in stellate ganglia due to CFR may play a role in growing risk of cardiovascular diseases.
T2  - Journal of Biological Regulators and Homeostatic Agents
T1  - Effect of Chronic Forced Running on Gene Expression of Catecholamine Biosynthetic Enzymes in Stellate Ganglia of Rats
VL  - 26
IS  - 3
SP  - 367
EP  - 377
ER  - 
@article{
author = "Gavrilović, Ljubica and Mandušić, Vesna and Stojiljković, Vesna and Kasapović, Jelena and Stojiljkovic, S. and Pajović, Snežana B. and Dronjak, Slađana",
year = "2012",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5112",
abstract = "The sympathoneural system has a profound influence on the heart function. Sympathetic neurons are the major contributors to the huge rise of circulating noradrenaline (NA) level in response to stressful stimuli. Treadmill training in rats is forced exercise which has the propensity to induce both psychological and physical stress. The aim of this study is to examine how chronic forced running (CFR) affects the expression of catecholamine biosynthetic enzymes (tyrosine hydroxylase (TH), dopamine-beta-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT)) and cAMP response element-binding (CREB) in stellate ganglia, as well as the concentrations of catecholamines, adrenocorticotropic hormone (ACTH) and corticosterone (CORT) in the plasma of rats. Also, we investigated how the additional acute immobilization stress changes the mentioned parameters. The rat training program consisted of 12 weeks running on a treadmill (20 m/min, 20 min/day). We found that CFR increases TH and DBH mRNA and protein levels in stellate ganglia, which is followed by increased NA concentration in the plasma. CFR reduces the level of PNMT m RNA, while the level of PNMT protein remains unchanged in stellate ganglia. The increased expression of TH and DBH genes positively correlates with the expression of CREB in stellate ganglia and with plasma ACTH level, while reduced level of PNMT mRNA in stellate ganglia correlates with reduced plasma CORT level. The additional acute immobilization stress increased gene expression of catecholamine biosynthetic enzymes in stellate ganglia, as well as catecholamines, ACTH and CORT levels in the plasma. The results presented here suggest that the continuous increase of the noradrenaline biosynthetic enzyme expression in stellate ganglia due to CFR may play a role in growing risk of cardiovascular diseases.",
journal = "Journal of Biological Regulators and Homeostatic Agents",
title = "Effect of Chronic Forced Running on Gene Expression of Catecholamine Biosynthetic Enzymes in Stellate Ganglia of Rats",
volume = "26",
number = "3",
pages = "367-377"
}
3

Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer

Mandušić, Vesna; Dimitrijević, Bogomir B.; Nikolic-Vukosavljevic, Dragica; Neskovic-Konstantinovic, Zora; Kanjer, Ksenija; Hamann, Ute

(2012)

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
AU  - Nikolic-Vukosavljevic, Dragica
AU  - Neskovic-Konstantinovic, Zora
AU  - Kanjer, Ksenija
AU  - Hamann, Ute
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5002
AB  - Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
T2  - Cancer Letters
T1  - Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer
VL  - 321
IS  - 1
SP  - 73
EP  - 79
DO  - 10.1016/j.canlet.2012.02.022
ER  - 
@article{
author = "Mandušić, Vesna and Dimitrijević, Bogomir B. and Nikolic-Vukosavljevic, Dragica and Neskovic-Konstantinovic, Zora and Kanjer, Ksenija and Hamann, Ute",
year = "2012",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/5002",
abstract = "Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.",
journal = "Cancer Letters",
title = "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer",
volume = "321",
number = "1",
pages = "73-79",
doi = "10.1016/j.canlet.2012.02.022"
}
9
6
11

Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats

Sudar, Emina; Dobutovic, Branislava; Soskić, Sanja S.; Mandušić, Vesna; Žakula, Zorica; Misirkić, Maja; Vucicevic, Ljubica; Janjetović, Kristina D.; Trajković, Vladimir S.; Mikhailidis, Dimitri P.; Isenović, Esma R.

(2011)

TY  - JOUR
AU  - Sudar, Emina
AU  - Dobutovic, Branislava
AU  - Soskić, Sanja S.
AU  - Mandušić, Vesna
AU  - Žakula, Zorica
AU  - Misirkić, Maja
AU  - Vucicevic, Ljubica
AU  - Janjetović, Kristina D.
AU  - Trajković, Vladimir S.
AU  - Mikhailidis, Dimitri P.
AU  - Isenović, Esma R.
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4317
AB  - The purpose of this study was to examine the effects of ghrelin on protein kinase B (Akt) and mitogen-activated protein kinase p42/44 (ERK1/2) activation as well as ghrelin effects on inducible nitric oxide (NO) synthase (iNOS; for gene Nos2) activity/expression in rat hearts. Male Wistar rats were treated with ghrelin (0.3 nmol/5 mu l) or an equal volume of phosphate-buffered saline, injected every 24 h into the lateral cerebral ventricle for 5 days and 2 h after the last treatment the animals were sacrificed. Serum NO, l-arginine (l-Arg), and arginase activity were measured spectrophotometrically. For phosphorylation of Akt, ERK1/2, and iNOS protein expression, Western blot method was used. The expression of Nos2 mRNA was measured by the quantitative real-time polymerase chain reaction (qRT-PCR). Treatment with ghrelin significantly increased NO production in serum by 1.4-fold compared with control. The concentration of l-Arg was significantly higher in ghrelin-treated rats than in control while arginase activity was significantly lower in ghrelin-treated than in control hearts. Ghrelin treatment increased phosphorylation of Akt by 1.9-fold and ERK1/2 by 1.6-fold and increased iNOS expression by 2.5-fold compared with control. In addition, ghrelin treatment increased Nos2 gene expression by 2.2-fold as determined by qRT-PCR. These results indicate that ghrelin regulation of iNOS expression/activity is mediated via Akt/ERK1/2 signaling pathway. These results may be relevant to understanding molecular mechanisms underlying direct cardiovascular actions of ghrelin.
T2  - Journal of Physiology and Biochemistry
T1  - Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats
VL  - 67
IS  - 2
SP  - 195
EP  - 204
DO  - 10.1007/s13105-010-0063-1
ER  - 
@article{
author = "Sudar, Emina and Dobutovic, Branislava and Soskić, Sanja S. and Mandušić, Vesna and Žakula, Zorica and Misirkić, Maja and Vucicevic, Ljubica and Janjetović, Kristina D. and Trajković, Vladimir S. and Mikhailidis, Dimitri P. and Isenović, Esma R.",
year = "2011",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4317",
abstract = "The purpose of this study was to examine the effects of ghrelin on protein kinase B (Akt) and mitogen-activated protein kinase p42/44 (ERK1/2) activation as well as ghrelin effects on inducible nitric oxide (NO) synthase (iNOS; for gene Nos2) activity/expression in rat hearts. Male Wistar rats were treated with ghrelin (0.3 nmol/5 mu l) or an equal volume of phosphate-buffered saline, injected every 24 h into the lateral cerebral ventricle for 5 days and 2 h after the last treatment the animals were sacrificed. Serum NO, l-arginine (l-Arg), and arginase activity were measured spectrophotometrically. For phosphorylation of Akt, ERK1/2, and iNOS protein expression, Western blot method was used. The expression of Nos2 mRNA was measured by the quantitative real-time polymerase chain reaction (qRT-PCR). Treatment with ghrelin significantly increased NO production in serum by 1.4-fold compared with control. The concentration of l-Arg was significantly higher in ghrelin-treated rats than in control while arginase activity was significantly lower in ghrelin-treated than in control hearts. Ghrelin treatment increased phosphorylation of Akt by 1.9-fold and ERK1/2 by 1.6-fold and increased iNOS expression by 2.5-fold compared with control. In addition, ghrelin treatment increased Nos2 gene expression by 2.2-fold as determined by qRT-PCR. These results indicate that ghrelin regulation of iNOS expression/activity is mediated via Akt/ERK1/2 signaling pathway. These results may be relevant to understanding molecular mechanisms underlying direct cardiovascular actions of ghrelin.",
journal = "Journal of Physiology and Biochemistry",
title = "Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats",
volume = "67",
number = "2",
pages = "195-204",
doi = "10.1007/s13105-010-0063-1"
}
21
19
23

Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas

Mandušić, Vesna; Popov-Celeketic, Dusan; Neskovic-Konstantinovic, Zora; Kanjer, Ksenija; Božović, Ana M.; Nikolic-Vukosavljevic, Dragica

(2010)

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Popov-Celeketic, Dusan
AU  - Neskovic-Konstantinovic, Zora
AU  - Kanjer, Ksenija
AU  - Božović, Ana M.
AU  - Nikolic-Vukosavljevic, Dragica
PY  - 2010
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4046
AB  - It is well known that breast tumors which are estrogen positive ER(+) are more likely to respond to hormone therapy. However, a certain percentage of ER(+)/PR(+) tumors do not respond to this therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ER), as well as the existence of numerous isoforms/splice variants of both ER alpha and ER beta, suggests that a complex regulation of estrogen action exists. In this study, we analyzed the expression ratio of ER beta 1 isoform and ER beta Delta 5 splice variant mRNAs, and its correlation with ER/PR status by quantitative RT-PCR and clinical and histopathological parameters. We found that the relative proportion of ER beta Delta 5 in the total ER beta 1 transcript pool inversely correlates with the PR level (rho = -0,359, p LT 0,003, Spearman). It may be that the ER beta Delta 5 variant modulates the ERa activity of downstream targets. In addition, we suggest that the determination of the expression profiles of ER alpha and ER beta isoforms and splice variants in the defined groups of patients are necessary for elucidating their involvement in endocrine resistance.
T2  - Archives of biological sciences
T1  - Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas
VL  - 62
IS  - 2
SP  - 257
EP  - 262
DO  - 10.2298/ABS1002257M
ER  - 
@article{
author = "Mandušić, Vesna and Popov-Celeketic, Dusan and Neskovic-Konstantinovic, Zora and Kanjer, Ksenija and Božović, Ana M. and Nikolic-Vukosavljevic, Dragica",
year = "2010",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/4046",
abstract = "It is well known that breast tumors which are estrogen positive ER(+) are more likely to respond to hormone therapy. However, a certain percentage of ER(+)/PR(+) tumors do not respond to this therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ER), as well as the existence of numerous isoforms/splice variants of both ER alpha and ER beta, suggests that a complex regulation of estrogen action exists. In this study, we analyzed the expression ratio of ER beta 1 isoform and ER beta Delta 5 splice variant mRNAs, and its correlation with ER/PR status by quantitative RT-PCR and clinical and histopathological parameters. We found that the relative proportion of ER beta Delta 5 in the total ER beta 1 transcript pool inversely correlates with the PR level (rho = -0,359, p LT 0,003, Spearman). It may be that the ER beta Delta 5 variant modulates the ERa activity of downstream targets. In addition, we suggest that the determination of the expression profiles of ER alpha and ER beta isoforms and splice variants in the defined groups of patients are necessary for elucidating their involvement in endocrine resistance.",
journal = "Archives of biological sciences",
title = "Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas",
volume = "62",
number = "2",
pages = "257-262",
doi = "10.2298/ABS1002257M"
}
1
1
1

Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance

Nikolic-Vukosavljevic, D.; Mandušić, Vesna; Neskovic-Konstantinovic, Z.; Dimitrijević, Bogomir B.

(2007)

TY  - CONF
AU  - Nikolic-Vukosavljevic, D.
AU  - Mandušić, Vesna
AU  - Neskovic-Konstantinovic, Z.
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3479
C3  - Breast
T1  - Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance
VL  - 16
SP  - S13
EP  - S14
DO  - 10.1016/S0960-9776(07)70069-3
ER  - 
@conference{
author = "Nikolic-Vukosavljevic, D. and Mandušić, Vesna and Neskovic-Konstantinovic, Z. and Dimitrijević, Bogomir B.",
year = "2007",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/3479",
journal = "Breast",
title = "Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance",
volume = "16",
pages = "S13-S14",
doi = "10.1016/S0960-9776(07)70069-3"
}

Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.

Mandušić, Vesna; Krtolica-Žikić, Koviljka; Nikolic-Vukosavljevic, Dragica; Popov-Celeketic, D.; Plećaš, D.; Boricic, I.; Dimitrijević, Bogomir B.; Tanić, Nikola

(2007)

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Krtolica-Žikić, Koviljka
AU  - Nikolic-Vukosavljevic, Dragica
AU  - Popov-Celeketic, D.
AU  - Plećaš, D.
AU  - Boricic, I.
AU  - Dimitrijević, Bogomir B.
AU  - Tanić, Nikola
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/3414
T2  - Archives of biological sciences
T1  - Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.
VL  - 59
IS  - 2
SP  - 15P
EP  - 16P
DO  - 10.2298/ABS070215PM
ER  - 
@article{
author = "Mandušić, Vesna and Krtolica-Žikić, Koviljka and Nikolic-Vukosavljevic, Dragica and Popov-Celeketic, D. and Plećaš, D. and Boricic, I. and Dimitrijević, Bogomir B. and Tanić, Nikola",
year = "2007",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/3414",
journal = "Archives of biological sciences",
title = "Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.",
volume = "59",
number = "2",
pages = "15P-16P",
doi = "10.2298/ABS070215PM"
}

Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer

Mandušić, Vesna; Nikolic-Vukosavljevic, Dragica; Tanić, Nikola; Kanjer, Ksenija; Neskovic-Konstantinovic, Zora; Celeketic, Dusica; Dimitrijević, Bogomir B.

(2007)

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Nikolic-Vukosavljevic, Dragica
AU  - Tanić, Nikola
AU  - Kanjer, Ksenija
AU  - Neskovic-Konstantinovic, Zora
AU  - Celeketic, Dusica
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2576
AB  - Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.
T2  - Journal of Cancer Research and Clinical Oncology
T1  - Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer
VL  - 133
IS  - 8
SP  - 571
EP  - 579
DO  - 10.1007/s00432-007-0209-x
ER  - 
@article{
author = "Mandušić, Vesna and Nikolic-Vukosavljevic, Dragica and Tanić, Nikola and Kanjer, Ksenija and Neskovic-Konstantinovic, Zora and Celeketic, Dusica and Dimitrijević, Bogomir B.",
year = "2007",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/2576",
abstract = "Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.",
journal = "Journal of Cancer Research and Clinical Oncology",
title = "Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer",
volume = "133",
number = "8",
pages = "571-579",
doi = "10.1007/s00432-007-0209-x"
}
3
14
14
19

Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy

Vranić-Mandušić, Vesna; Subota, V; Savovski, K; Medic, L; Dramićanin, Tatjana; Jozanov-Stankov, O; Popov-Celeketic, D; Jokanović, Milan; Dimitrijević, Bogomir B.

(2004)

TY  - JOUR
AU  - Vranić-Mandušić, Vesna
AU  - Subota, V
AU  - Savovski, K
AU  - Medic, L
AU  - Dramićanin, Tatjana
AU  - Jozanov-Stankov, O
AU  - Popov-Celeketic, D
AU  - Jokanović, Milan
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2701
AB  - Tiazofurin (TZF) is a cytostatic drug that leads to depletion of the GTP pool in tumor and normal cells via its active metabolite tiazofurin-adenine dinucleotide (TAD). TAD was detected in different cell lines, but not in erythrocytes, so the mechanism of erythrocytotoxicity of TZF remains unclear. The purpose of this study was to evaluate in vitro and in vivo action of tiazofurin on rat erythrocytes (RBC). After two decades of clinical trials the question of erythrocytotoxicity of TZF had remained unexplained making this study justified. Since we have previously demonstrated early erythrocytotoxic effects in male Wistar rats, we extend this finding on isolated RBC. Isolated erythrocytes from untreated animals were treated in buffered solution or plasma containing TZF In addition, groups of 10 rats were treated with 200 and 1000 mg/kg of TZF and hematologic parameters were analyzed by flowcytometry and by the analysis of the peripheral blood smears. Early signs of hemolysis or aberrant structures were monitored by scanning probe microscopy (SPM). We suggest that correlation exists between early erythrocytotoxicity and irregularities in erythrocyte morphology and membrane integrity. We also found that TZF affects responsiveness to oxidative stress. This is in concordance with flowcytometric findings describing anisocytosis and anisochromosis of RBC. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
T2  - Toxicology Letters
T1  - Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy
VL  - 146
IS  - 3
SP  - 275
EP  - 284
DO  - 10.1016/j.toxlet.2003.10.013
ER  - 
@article{
author = "Vranić-Mandušić, Vesna and Subota, V and Savovski, K and Medic, L and Dramićanin, Tatjana and Jozanov-Stankov, O and Popov-Celeketic, D and Jokanović, Milan and Dimitrijević, Bogomir B.",
year = "2004",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/2701",
abstract = "Tiazofurin (TZF) is a cytostatic drug that leads to depletion of the GTP pool in tumor and normal cells via its active metabolite tiazofurin-adenine dinucleotide (TAD). TAD was detected in different cell lines, but not in erythrocytes, so the mechanism of erythrocytotoxicity of TZF remains unclear. The purpose of this study was to evaluate in vitro and in vivo action of tiazofurin on rat erythrocytes (RBC). After two decades of clinical trials the question of erythrocytotoxicity of TZF had remained unexplained making this study justified. Since we have previously demonstrated early erythrocytotoxic effects in male Wistar rats, we extend this finding on isolated RBC. Isolated erythrocytes from untreated animals were treated in buffered solution or plasma containing TZF In addition, groups of 10 rats were treated with 200 and 1000 mg/kg of TZF and hematologic parameters were analyzed by flowcytometry and by the analysis of the peripheral blood smears. Early signs of hemolysis or aberrant structures were monitored by scanning probe microscopy (SPM). We suggest that correlation exists between early erythrocytotoxicity and irregularities in erythrocyte morphology and membrane integrity. We also found that TZF affects responsiveness to oxidative stress. This is in concordance with flowcytometric findings describing anisocytosis and anisochromosis of RBC. (C) 2003 Elsevier Ireland Ltd. All rights reserved.",
journal = "Toxicology Letters",
title = "Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy",
volume = "146",
number = "3",
pages = "275-284",
doi = "10.1016/j.toxlet.2003.10.013"
}
9
10
10

Hematological toxicity associated with tiazofurin-influence on erythropoiesis

Vranić, Vesna; Savovski, K; Dedović-Tanić, Nasta; Dimitrijević, Bogomir B.

(2000)

TY  - JOUR
AU  - Vranić, Vesna
AU  - Savovski, K
AU  - Dedović-Tanić, Nasta
AU  - Dimitrijević, Bogomir B.
PY  - 2000
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2335
AB  - In this study hematological toxicity was analyzed after the single and repeated applications of tiazofurin (TZF). Cellularity of bone marrow, spleen and peripheral blood was examined, spanning the period of fifty days after the initial application. Analysis of hematological parameters was performed by slightly modified conventional techniques. The fraction of erythroid series was monitored during the experiment. Presented data describe kinetics of damage and recovery of hemopoietic tissue. Our results indicate that the effect of tiazofurin on cellularity of bone marrow and spleen and on erythropoiesis is reversible and dose dependent within tested dose range and therapeutic regimes. Twenty days after the application normal function of hemopoietic tissues was restored. This approach and results can be useful in defining the timing for sequencing and combination therapy with tiazofurin. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
T2  - Toxicology Letters
T1  - Hematological toxicity associated with tiazofurin-influence on erythropoiesis
VL  - 114
IS  - 1-3
SP  - 81
EP  - 90
DO  - 10.1016/S0378-4274(99)00269-6
ER  - 
@article{
author = "Vranić, Vesna and Savovski, K and Dedović-Tanić, Nasta and Dimitrijević, Bogomir B.",
year = "2000",
url = "http://vinar.vin.bg.ac.rs/handle/123456789/2335",
abstract = "In this study hematological toxicity was analyzed after the single and repeated applications of tiazofurin (TZF). Cellularity of bone marrow, spleen and peripheral blood was examined, spanning the period of fifty days after the initial application. Analysis of hematological parameters was performed by slightly modified conventional techniques. The fraction of erythroid series was monitored during the experiment. Presented data describe kinetics of damage and recovery of hemopoietic tissue. Our results indicate that the effect of tiazofurin on cellularity of bone marrow and spleen and on erythropoiesis is reversible and dose dependent within tested dose range and therapeutic regimes. Twenty days after the application normal function of hemopoietic tissues was restored. This approach and results can be useful in defining the timing for sequencing and combination therapy with tiazofurin. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.",
journal = "Toxicology Letters",
title = "Hematological toxicity associated with tiazofurin-influence on erythropoiesis",
volume = "114",
number = "1-3",
pages = "81-90",
doi = "10.1016/S0378-4274(99)00269-6"
}
3
5
4